Clinical Trials Browser

Hyperprolactinemia, Prolactinoma

NCT07045935 2025-09-23

ProBOLIC

Phase 4 Recruiting

60 enrolled

Prolactin Deficiency, Isolated, Hyperprolactinemia, Prolactinoma

NCT03038308 2024-06-04

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Phase 1/2 Completed

16 enrolled 8 charts

Hyperprolactinemia, Prolactinoma

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Phase 2 Withdrawn

CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT04107480 2020-07-20

PRolaCT - Three Prolactinoma RCTs

Phase 4 Unknown

880 enrolled

Prolactinoma

NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Phase NA Unknown

68 enrolled

Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase 2 Completed

9 enrolled 11 charts

Endocrine

Pituitary Neoplasms, Prolactinoma

NCT03717454 2018-11-20

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

Phase NA Unknown

50 enrolled

Prolactinoma

NCT03400865 2018-10-16

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

Phase NA Unknown

30 enrolled

Prolactinoma, Disease Resistance

NCT03353025 2017-11-24

TNAPA

Phase NA Unknown

394 enrolled

Prolactinoma

NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Phase 2/3 Completed

21 enrolled 4 charts

Prolactinoma

NCT01775332 2015-07-31

Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools

Phase NA Unknown

60 enrolled

Endocrine

Gigantism, Pituitary Neoplasms, Prolactinoma, Growth Hormone-Secreting Pituitary Adenoma, ACTH-Secreting Pituitary Adenoma

NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase 1 Terminated

129 enrolled

CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT01143584 2010-06-14

Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.

Phase NA Unknown

20 enrolled

Prolactinoma

NCT00697814 2008-06-16

Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Phase 2 Completed

15 enrolled

Hypogonadism, Prolactinoma

Clinical Trials

SPARAGMOS

ProBOLIC

Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Temozolomide in Treating Patients With Invasive Pituitary Tumors

PRolaCT - Three Prolactinoma RCTs

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

TNAPA

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.

Clomiphene in Males With Prolactinomas and Persistent Hypogonadism